Back to Resource Library
Long-Acting Injectable Cabotegravir for HIV Prevention: What do we know and need to know about the risks and consequences of cabotegravir resistance?
4 October 2022
This article from The Science of Prevention summarizes what is known about cabotegravir (CAB) pharmacokinetics, activity, and emergence of resistance from in vitro, macaque and clinical studies, and evaluates the risk of resistance from CAB for PrEP with on-time injections and after CAB for PrEP discontinuation.